PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Nick Corriveau-Lecavalier

Department of Neurology, Mayo Clinic, Rochester, MN.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 5, 2026 · JOURNAL ARTICLE

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.

Neurology

Retrospective eligibility analysis demonstrating that 70–85% of biomarker-confirmed atypical AD patients would be ineligible for anti-amyloid therapies, primarily due to cognitive thresholds misaligned with disease severity.

Important Confirmatory EvidenceNick Corriveau-Lecavalier Vijay K Ramanan Biomarkers

Reported

Sample size184

PCA subgroup98 (53.3%)

lvPPA subgroup42 (22.8%)

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support